Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Hartter, S' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 37 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Weigmann, H; Hartter, S; Maehrlein, S; Kiefer, W; Kramer, G; Dannhardt, G; Hiemke, C
      Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography

      JOURNAL OF CHROMATOGRAPHY B
    2. Hartter, S; Wang, XM; Weigmann, H; Friedberg, T; Arand, M; Oesch, F; Hiemke, C
      Differential effects of fluvoxamine and other antidepressants on the biotransformation of melatonin

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    3. Muller, MJ; Hartter, S; Kohler, D; Hiemke, C
      Serum levels of sulpiride enantiomers after oral treatment with racemic sulpiride in psychiatric patients: A pilot study

      PHARMACOPSYCHIATRY
    4. Weigmann, H; Gerek, S; Zeisig, A; Muller, M; Hartter, S; Hiemke, C
      Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: Evidence from a therapeutic drug monitoring service

      THERAPEUTIC DRUG MONITORING
    5. Hartter, S; Morita, S; Bodin, K; Ursing, C; Tybring, G; Bertilsson, L
      Determination of exogenous melatonin and its 6-hydroxy metabolite in humanplasma by liquid chromatography-mass spectrometry

      THERAPEUTIC DRUG MONITORING
    6. Laine, K; Tybring, G; Hartter, S; Andersson, K; Svensson, JO; Widen, J; Bertilsson, L
      Inhibition of cytochrome P4502D6 activity with paroxetine normalizes the ultrarapid metabolizer phenotype as measured by nortriptyline pharmacokinetics and the debrisoquin test

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    7. Hartter, S; Ursing, C; Morita, S; Tybring, G; von Bahr, C; Christensen, M; Rojdmark, S; Bertilsson, L
      Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    8. Hartter, S; Weigmann, H; Hiemke, C
      Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection

      JOURNAL OF CHROMATOGRAPHY B
    9. Weigmann, H; Hartter, S; Bagli, M; Hiemke, C
      Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    10. Hiemke, C; Hartter, S
      Pharmacokinetics of selective serotonin reuptake inhibitors

      PHARMACOLOGY & THERAPEUTICS
    11. Hartter, S; Grozinger, M; Weigmann, H; Roschke, J; Hiemke, C
      Increased bioavailability of oral melatonin after fluvoxamine coadministration

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    12. Grozinger, M; Hartter, S; Wang, XM; Roschke, J; Hiemke, C
      Fluvoxamine strongly inhibits melatonin metabolism in a patient with low-amplitude melatonin profile

      ARCHIVES OF GENERAL PSYCHIATRY
    13. Weigmann, H; Hartter, S; Fischer, V; Dahmen, N; Hiemke, C
      Distribution of clozapine and desmethylclozapine between blood and brain in rats

      EUROPEAN NEUROPSYCHOPHARMACOLOGY
    14. Grozinger, M; Hartter, S; Hiemke, C; Roschke, J
      Oxybutynin enhances the metabolism of clomipramine and dextrorphan possibly by induction of a cytochrome P450 isoenzyme

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    15. Szegedi, A; Anghelescu, I; Wiesner, J; Schlegel, S; Weigmann, H; Hartter, S; Hiemke, C; Wetzel, H
      Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: Drug monitoring and tolerability data from a prospective clinical trial

      PHARMACOPSYCHIATRY
    16. Lammers, CH; Deuschle, M; Weigmann, H; Hartter, S; Hiemke, C; Heese, C; Heuser, I
      Coadministration of clozapine and fluvoxamine in psychotic patients - Clinical experience

      PHARMACOPSYCHIATRY
    17. HARTTER S; JENSEN B; HIEMKE C; LEAL M; WEIGMANN H; UNGER K
      MICELLAR ELECTROKINETIC CAPILLARY CHROMATOGRAPHY FOR THERAPEUTIC DRUG-MONITORING OF CARBAMAZEPINE AND ITS MAIN METABOLITES

      Journal of chromatography B. Biomedical sciences and applications
    18. WEIGMANN H; HARTTER S; HIEMKE C
      AUTOMATED-DETERMINATION OF CLOMIPRAMINE AND ITS MAJOR METABOLITES IN HUMAN AND RAT SERUM BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ONLINE COLUMN-SWITCHING

      Journal of chromatography B. Biomedical sciences and applications
    19. GROZINGER M; HARTTER S; HIEMKE C; GRIESE EU; ROSCHKE J
      INTERACTION OF MODAFINIL AND CLOMIPRAMINE AS COMEDICATION IN A NARCOLEPTIC PATIENT

      Clinical neuropharmacology
    20. WETZEL H; ANGHELESCU I; SZEGEDI A; WIESNER J; WEIGMANN H; HARTTER S; HIEMKE C
      PHARMACOKINETIC INTERACTIONS OF CLOZAPINE WITH SELECTIVE SEROTONIN REUPTAKE INHIBITORS - DIFFERENTIAL-EFFECTS OF FLUVOXAMINE AND PAROXETINEIN A PROSPECTIVE-STUDY

      Journal of clinical psychopharmacology
    21. HARTTER S; WETZEL H; HAMMES E; TORKZADEH M; HIEMKE C
      SERUM CONCENTRATIONS OF FLUVOXAMINE AND CLINICAL EFFECTS - A PROSPECTIVE OPEN CLINICAL-TRIAL

      Pharmacopsychiatry
    22. SANDMANN J; LORCH B; BANDELOW B; HARTTER S; WINTER P; HIEMKE C; BENKERT O
      FLUVOXAMINE OR PLACEBO IN THE TREATMENT OF PANIC DISORDER AND RELATIONSHIP TO BLOOD-CONCENTRATIONS OF FLUVOXAMINE

      Pharmacopsychiatry
    23. HARTTER S; WETZEL H; HAMMES E; TORKZADEH M; HIEMKE C
      NONLINEAR PHARMACOKINETICS OF FLUVOXAMINE AND GENDER DIFFERENCES

      Therapeutic drug monitoring
    24. Hartter, S; Dingeldein, E; Bonath, KH
      Replacement parts of bone - therapeutic agents of future in small animal practice

      KLEINTIERPRAXIS
    25. HARTTER S; DINGEMANSE J; BAIER D; ZIEGLER G; HIEMKE C
      INHIBITION OF DEXTROMETHORPHAN METABOLISM BY MOCLOBEMIDE

      Psychopharmacology
    26. KOHLER D; HARTTER S; FUCHS K; SIEGHART W; HIEMKE C
      CYP2D6 GENOTYPE AND PHENOTYPING BY DETERMINATION OF DEXTROMETHORPHAN AND METABOLITES IN SERUM OF HEALTHY CONTROLS AND OF PATIENTS UNDER PSYCHOTROPIC MEDICATION

      Pharmacogenetics
    27. BANGER M; HERMES B; HARTTER S; HIEMKE C
      MONITORING SERUM CONCENTRATIONS OF CLOMIPRAMINE AND METABOLITES - FLUORESCENCE POLARIZATION IMMUNOASSAY VERSUS HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Pharmacopsychiatry
    28. WEIGMANN H; BIERBRAUER J; HARTTER S; HIEMKE C
      AUTOMATED-DETERMINATION OF CLOZAPINE AND MAJOR METABOLITES IN SERUM AND URINE

      Therapeutic drug monitoring
    29. DEUSCHLE M; HARTTER S; HIEMKE C; STANDHARDT H; HEUSER I
      DOXEPIN AND ITS METABOLITES IN PLASMA AND CEREBROSPINAL-FLUID IN DEPRESSED-PATIENTS

      Psychopharmacology
    30. HARTTER S; DINGEMANSE J; BAIER D; ZIEGLER G; HIEMKE C
      THE ROLE OF CYTOCHROME-P450 2D6 IN THE METABOLISM OF MOCLOBEMIDE

      European neuropsychopharmacology
    31. HARTTER S; BAIER D; DINGEMANSE J; ZIEGLER G; HIEMKE C
      AUTOMATED-DETERMINATION OF DEXTROMETHORPHAN AND ITS MAIN METABOLITES IN HUMAN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY AND COLUMN-SWITCHING

      Therapeutic drug monitoring
    32. SZEGEDI A; WETZEL H; LEAL M; HARTTER S; HIEMKE C
      COMBINATION TREATMENT WITH CLOMIPRAMINE AND FLUVOXAMINE - DRUG-MONITORING, SAFETY, AND TOLERABILITY DATA

      The Journal of clinical psychiatry
    33. HARTTER S; HERMES B; HIEMKE C
      AUTOMATED-DETERMINATION OF TRIMIPRAMINE AND N-DESMETHYLTRIMIPRAMINE IN HUMAN PLASMA OR SERUM BY HPLC WITH ONLINE SOLID-PHASE EXTRACTION

      Journal of liquid chromatography
    34. HARTTER S; ARAND M; OESCH F; HIEMKE C
      NONCOMPETITIVE INHIBITION OF CLOMIPRAMINE N-DEMETHYLATION BY FLUVOXAMINE

      Psychopharmacology
    35. HIEMKE C; WEIGMANN H; HARTTER S; DAHMEN N; WETZEL H; MULLER H
      ELEVATED LEVELS OF CLOZAPINE IN SERUM AFTER ADDITION OF FLUVOXAMINE

      Journal of clinical psychopharmacology
    36. HARTTER S; HERMES B; SZEGEDI A; HIEMKE C
      AUTOMATED-DETERMINATION OF PAROXETINE AND ITS MAIN METABOLITE BY COLUMN-SWITCHING AND ONLINE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Therapeutic drug monitoring
    37. RAO ML; STABEROCK U; BAUMANN P; HIEMKE C; DEISTER A; CUENDET C; AMEY M; HARTTER S; KRAEMER M
      MONITORING TRICYCLIC ANTIDEPRESSANT CONCENTRATIONS IN SERUM BY FLUORESCENCE POLARIZATION IMMUNOASSAY COMPARED WITH GAS-CHROMATOGRAPHY AND HPLC

      Clinical chemistry


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 12:03:47